Related Experiment Video
Updated: Jun 29, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How
Khawaja Hassan Akhtar1, Usman Baber1
1Department of Medicine, Section of Cardiovascular Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Insights
Dual antiplatelet therapy (DAPT) after stenting reduces ischemic events but increases bleeding. Optimal DAPT duration balances these risks, guided by patient factors and time post-procedure.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard after drug-eluting stent placement.
- Recommended durations are at least 6 months for stable ischemic heart disease and 12 months for acute coronary syndrome.
Purpose of the Study:
- To review the balance between ischemic event reduction and bleeding risk with DAPT.
- To emphasize individualized DAPT duration decisions after percutaneous coronary intervention (PCI).
Main Methods:
- Literature review and clinical guideline synthesis.
- Analysis of risk-benefit trade-offs for DAPT duration.
Main Results:
- Extended DAPT reduces ischemic events but increases bleeding complications.
- Shorter DAPT durations are favored in patients with high bleeding risk.
Conclusions:
- DAPT duration decisions require careful clinical judgment.
- Individualized assessment of bleeding and ischemic risk is crucial.
- Time elapsed since revascularization is a key factor in DAPT duration decisions.
Abstract:
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended for at least 6 and 12 months following percutaneous coronary intervention with drug-eluting stents among patients with stable ischemic heart disease and acute coronary syndrome, respectively. Additional exposure to antiplatelet therapy reduces ischemic events but also increases bleeding risk. Conversely, shorter durations of DAPT are preferred among those at high bleeding risk. Hence, decisions surrounding duration of DAPT after revascularization should include clinical judgment, assessment of the risk of bleeding and ischemic events, and time after revascularization.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...